Mavacamten for treatment of symptomatic obstructive hypertrophic cardiomyopathy (EXPLORER-HCM): a randomised, double-blind, placebo-managed, section 3 trial



Cardiac muscle hypercontractility is a key pathophysiological abnormality in hypertrophic
cardiomyopathy, and a serious determinant of dynamic left ventricular outflow tract
(LVOT) obstruction. In the market pharmacological choices for hypertrophic cardiomyopathy
are insufficient or poorly tolerated and are no longer disease-explicit. We aimed to assess
the efficacy and security of mavacamten, a first-in-class cardiac myosin inhibitor,
in symptomatic obstructive hypertrophic cardiomyopathy.


On this section 3, randomised, double-blind, placebo-managed trial (EXPLORER-HCM)
in 68 medical cardiovascular centres in 13 worldwide locations, patients with hypertrophic
cardiomyopathy with an LVOT gradient of 50 mm Hg or increased and Recent York Coronary heart Affiliation
(NYHA) class II–III symptoms were assigned (1:1) to acquire mavacamten (beginning at
5 mg) or placebo for 30 weeks. Visits for evaluate of affected person site befell each and each
2–4 weeks. Serial reports incorporated echocardiogram, electrocardiogram, and blood
collection for laboratory exams and mavacamten plasma concentration. The principle endpoint
changed into a 1·5 mL/kg per min or increased extend in peak oxygen consumption (pVO
2) and no longer no longer as much as one NYHA class discount or a 3·0 mL/kg per min or increased pVO
2extend with out NYHA class worsening. Secondary endpoints assessed adjustments in post-articulate
LVOT gradient, pVO
2, NYHA class, Kansas Metropolis Cardiomyopathy Questionnaire-Scientific Summary Win (KCCQ-CSS),
and Hypertrophic Cardiomyopathy Symptom Questionnaire Shortness-of-Breath subscore
(HCMSQ-SoB). This watch is registered with,


Between Would perchance well 30, 2018, and July 12, 2019, 429 adults were assessed for eligibility,
of whom 251 (59%) were enrolled and randomly assigned to mavacamten (n=123 [49%])
or placebo (n=128 [51%]). 45 (37%) of 123 patients on mavacamten versus 22 (17%) of
128 on placebo met the predominant endpoint (difference +19·4%, 95% CI 8·7 to 30·1; p=0·0005).
Sufferers on mavacamten had increased reductions than these on placebo in post-articulate
LVOT gradient (−36 mm Hg, 95% CI −43·2 to −28·1; p2(+1·4 mL/kg per min, 0·6 to 2·1; p=0·0006), and improved symptom ratings (KCCQ-CSS
+9·1, 5·5 to 12·7; HCMSQ-SoB −1·8, −2·4 to −1·2; pvs40 of 128 patients in the placebo neighborhood; 95% CI 22·2 to 45·4; p


Remedy with mavacamten improved articulate capacity, LVOT obstruction, NYHA life like
class, and properly being site in patients with obstructive hypertrophic cardiomyopathy.
The outcomes of this pivotal trial highlight the advantages of disease-explicit treatment
for this situation.



This text is on hand free of tag.

Simply log in to entry the fat article, or register for free while you happen to manufacture no longer yet private a username and password.


  1. 1.
    • Marian AJ
    • Braunwald E

    Hypertrophic cardiomyopathy: genetics, pathogenesis, medical manifestations, prognosis, and treatment.

    Circ Res.2017;121:749-770

  2. 2.
    • Maron BJ

    Scientific direction and administration of hypertrophic cardiomyopathy.

    N Engl J Med.2018;379:655-668

  3. 3.
    • Seferović PM
    • Polovina M
    • Bauersachs J
    • et al.

    Coronary heart failure in cardiomyopathies: a inform paper from the Coronary heart Failure Affiliation of the European Society of Cardiology.

    Eur J Coronary heart Fail.2019;21:553-576

  4. 4.
    • Sequeira V
    • Bertero E
    • Maack C

    Bright drain utilizing hypertrophic cardiomyopathy.

    FEBS Lett.2019;593:1616-1626

  5. 5.
    • Ho CY
    • Day SM
    • Ashley EA
    • et al.

    Genotype and lifelong burden of disease in hypertrophic cardiomyopathy: insights from the sarcomeric human cardiomyopathy registry (SHaRe).


  6. 6.
    • Gersh BJ
    • Maron BJ
    • Bonow RO
    • et al.

    2011 ACCF/AHA guideline for the prognosis and treatment of hypertrophic cardiomyopathy: a file of the American College of Cardiology Foundation/American Coronary heart Affiliation Job Power on Notice Guidelines.


  7. 7.
    • Elliott PM
    • Anastasakis A
    • et al.
    • Authors/Job Power members

    2014 ESC Guidelines on prognosis and administration of hypertrophic cardiomyopathy: the Job Power for the Diagnosis and Administration of Hypertrophic Cardiomyopathy of the European Society of Cardiology (ESC).

    Eur Coronary heart J.2014;35:2733-2779

  8. 8.
    • Kaltenbach M
    • Hopf R
    • Kober G
    • Bussmann WD
    • Keller M
    • Petersen Y

    Remedy of hypertrophic obstructive cardiomyopathy with verapamil.

    Br Coronary heart J.1979;42:35-42

  9. 9.
    • Cohen LS
    • Braunwald E

    Amelioration of angina pectoris in idiopathic hypertrophic subaortic stenosis with beta-adrenergic blockade.


  10. 10.
    • Ammirati E
    • Contri R
    • Coppini R
    • Cecchi F
    • Frigerio M
    • Olivotto I

    Pharmacological treatment of hypertrophic cardiomyopathy: contemporary practice and current views.

    Eur J Coronary heart Fail.2016;18:1106-1118

  11. 11.
    • Liebregts M
    • Vriesendorp PA
    • Mahmoodi BK
    • Schinkel AF
    • Michels M
    • ten Berg JM

    A systematic evaluate and meta-diagnosis of long-interval of time outcomes after septal discount treatment in patients with hypertrophic cardiomyopathy.

    JACC Coronary heart Fail.2015;3:896-905

  12. 12.
    • Wells S
    • Rowin EJ
    • Boll G
    • et al.

    Scientific profile of nonresponders to surgical myectomy with obstructive hypertrophic cardiomyopathy.

    Am J Med.2018;131:e235-e239

  13. 13.
    • Kim LK
    • Swaminathan RV
    • Looser P
    • et al.

    Clinic quantity outcomes after septal myectomy and alcohol septal ablation for treatment of obstructive hypertrophic cardiomyopathy: US Nationwide Inpatient Database, 2003–2011.

    JAMA Cardiol.2016;1:324-332

  14. 14.
    • Grillo MP
    • Erve JCL
    • Dick R
    • et al.

    In vitro and in vivo pharmacokinetic characterization of mavacamten, a first-in-class runt molecule allosteric modulator of beta cardiac myosin.


  15. 15.
    • Kawas RF
    • Anderson RL
    • Ingle SRB
    • Tune Y
    • Sran AS
    • Rodriguez HM

    A runt-molecule modulator of cardiac myosin acts on a pair of stages of the myosin chemomechanical cycle.

    J Biol Chem.2017;292:16571-16577

  16. 16.
    • Anderson RL
    • Trivedi DV
    • Sarkar SS
    • et al.

    Decoding the tidy relaxed inform of human β-cardiac myosin and the mode of action of mavacamten from myosin molecules to muscle fibers.

    Proc Natl Acad Sci USA.2018;115:E8143-E8152

  17. 17.
    • del Rio CL
    • Ueyama Y
    • Baker DC
    • et al.

    In vivo cardiac results of mavacamten (MYK-461): proof for unfavorable inotropy and improved compliance.


  18. 18.
    • Green EM
    • Wakimoto H
    • Anderson RL
    • et al.

    A runt-molecule inhibitor of sarcomere contractility suppresses hypertrophic cardiomyopathy in mice.


  19. 19.
    • Heitner SB
    • Jacoby D
    • Lester SJ
    • et al.

    Mavacamten treatment for obstructive hypertrophic cardiomyopathy: a medical trial.

    Ann Intern Med.2019;170:741-748

  20. 20.
    • Ho CY
    • Mealiffe ME
    • Bach RG
    • et al.

    Review of mavacamten in symptomatic patients with nonobstructive hypertrophic cardiomyopathy.

    J Am Coll Cardiol.2020;75:2649-2660

  21. 21.
    • Ho CY
    • Olivotto I
    • Jacoby D
    • et al.

    Watch manufacture and rationale of EXPLORER-HCM: evaluation of mavacamten in adults with symptomatic obstructive hypertrophic cardiomyopathy.

    Circ Coronary heart Fail.2020;13e006853

  22. 22.
    • Lewis EF
    • Claggett BL
    • McMurray JJV
    • et al.

    Health-connected quality of lifestyles outcomes in PARADIGM-HF.

    Circ Coronary heart Fail.2017;10e003430

  23. 23.
    • Cowger JA
    • Naka Y
    • Aaronson KD
    • et al.

    Quality of lifestyles and life like capacity outcomes in the MOMENTUM 3 trial at 6 months: a demand novel metrics for left ventricular abet application patients.

    J Coronary heart Lung Transplant.2018;37:15-24

  24. 24.
    • Kubo T
    • Kitaoka H
    • Okawa M
    • et al.

    Blended measurements of cardiac troponin I and brain natriuretic peptide are priceless for predicting harmful outcomes in hypertrophic cardiomyopathy.

    Circ J.2011;75:919-926

  25. 25.
    • Geske JB
    • McKie PM
    • Ommen SR
    • Sorajja P

    B-kind natriuretic peptide and survival in hypertrophic cardiomyopathy.

    J Am Coll Cardiol.2013;61:2456-2460

  26. 26.
    • Seydelmann N
    • Liu D
    • Krämer J
    • et al.

    Excessive-sensitivity troponin: a medical blood biomarker for staging cardiomyopathy in Fabry disease.

    J Am Coronary heart Assoc.2016;5e002839

  27. 27.
    • Nielen JTH
    • de Vries F
    • van der Velde JHPM
    • et al.

    The affiliation between β-blocker spend and cardiorespiratory fitness: the maastricht watch.

    J Cardiovasc Pharmacol Ther.2019;24:37-45

  28. 28.
    • Malhotra R
    • Bakken Okay
    • D’Elia E
    • Lewis GD

    Cardiopulmonary articulate checking out in heart failure.

    JACC Coronary heart Fail.2016;4:607-616

  29. 29.
    • Myers J
    • Gujja P
    • Neelagaru S
    • Burkhoff D

    Cardiac output and cardiopulmonary responses to articulate in heart failure: application of a brand new bio-reactance application.

    J Card Fail.2007;13:629-636

Article Files

E-newsletter Ancient past

Printed: August 29, 2020




© 2020 Elsevier Ltd. All rights reserved.


Web entry to this text on ScienceDirect

Linked Articles



Please enter your comment!
Please enter your name here

This site uses Akismet to reduce spam. Learn how your comment data is processed.